In a report published Friday, UBS analyst Andrew Peters initiated coverage of Prothena Corporation PLC (NASDAQ: PRTA) with a Buy rating and $58 price target, following an analysis of the company' lead drug programs.
"We believe early data for NEOD001 are clearly suggestive of an active therapy in a high unmet need indication, with near-term data positioned to increase our and investor confidence on the clinical profile of the phase-3 asset," Peters said.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The analyst believes that the revenue potential and catalyst capabilities of NEOD001 in the treatment of AL Amyliodosis are underappreciated by the market. Although the initial data is compelling, further updates at the ASCO would help investors better understand its clinical profile.
According to the UBS report, the potential of PRX002 in the treatment of Parkinson's disease is also underappreciated, given that it has a highly compelling rationale and strong partnership with Roche Holding Ltd., which offers significant economic support.
The analyst also believes that "given the broad pipeline in large market opportunities as well as an attractive Irish-tax base, we see the company as a top M&A target in smid-cap biotech."
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.